Update on systemic therapies of metastatic renal cell carcinoma

被引:0
作者
E. Herrmann
S. Bierer
C. Wülfing
机构
[1] University of Münster,Department of Urology
来源
World Journal of Urology | 2010年 / 28卷
关键词
Metastatic renal cell carcinoma; Sunitinib; Sorafenib; Temsirolimus; Everolimus; Bevacizumab;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:303 / 309
页数:6
相关论文
共 392 条
[1]  
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]  
Siegel R(2009)Incidence and long-term prognosis of papillary renal cell carcinoma J Cancer Res Clin Oncol 135 799-805
[3]  
Ward E(2005)Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience J Clin Oncol 23 2763-2771
[4]  
Hao Y(2003)Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma Am J Surg Pathol 27 612-624
[5]  
Xu J(2001)Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655-1659
[6]  
Murray T(2001)Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966-970
[7]  
Thun MJ(2003)Immunotherapy for renal cell carcinoma Eur Urol 44 65-75
[8]  
Schrader AJ(2007)Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125-134
[9]  
Rauer-Bruening S(2007)Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103-2111
[10]  
Olbert PJ(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Eng K Med 356 115-124